Cue Biopharma (CUE) Retained Earnings (2017 - 2025)

Cue Biopharma has disclosed Retained Earnings across 9 years of filings, most recently posting -$368.5 million for Q4 2025.

• Retained Earnings for Q4 2025 came in at -$368.5 million, down 7.78% year-over-year; the trailing twelve-month figure through Dec 2025 was -$368.5 million (down 7.78% YoY), and the FY2025 annual result was -$368.5 million, down 7.78% from the prior year.
• Retained Earnings came in at -$368.5 million for Q4 2025 at Cue Biopharma, down from $1000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $1000.0 in Q3 2025 to a low of -$368.5 million in Q4 2025.
• The 5-year median for Retained Earnings is -$276.8 million (2023), against an average of -$219.5 million.
• Across the five-year window, Retained Earnings plunged 803841.03% in 2024 and surged 100.0% in 2025, its largest moves.
• Cue Biopharma's Retained Earnings stood at -$189.1 million in 2021, then surged by 99.95% to -$96000.0 in 2022, then tumbled by 313639.58% to -$301.2 million in 2023, then fell by 13.5% to -$341.9 million in 2024, then declined by 7.78% to -$368.5 million in 2025.
• The last three Retained Earnings figures came in at -$368.5 million (Q4 2025), $1000.0 (Q3 2025), and -$362.6 million (Q2 2025), per Business Quant data.